PSA Cut Point of ≥0.4 ng/mL Predicts Progression

This article originally appeared here.
Share this content:
PSA Cut Point of ≥0.4 ng/mL Predicts Progression
PSA Cut Point of ≥0.4 ng/mL Predicts Progression

MONDAY, June 20, 2016 (HealthDay News) -- A prostate-specific antigen cut point of ≥0.4 ng/mL predicts future disease progression, according to a study published in the June issue of The Journal of Urology.

Amir Toussi, M.D., from the Mayo Clinic in Rochester, Minn., and colleagues reviewed long-term prostatectomy outcomes to examine the most appropriate prostate-specific antigen cut point that predicts subsequent disease progression. Data were included for 13,512 patients with cT1-2N0M0 prostate cancer who underwent radical prostatectomy.

The researchers found that a detectable prostate-specific antigen developed in 5,041 patients at a median postoperative follow-up of 9.1 years, and systemic progression developed in 512 patients. The percentage of patients experiencing a continued prostate-specific antigen increase over five years was 61, 67, and 74 percent, respectively, after reaching the prostate-specific antigen cut point of 0.2, 0.3, and 0.4 ng/mL, plateauing at 0.4 ng/mL. The strongest correlation between biochemical recurrence and systemic progression was seen for a single prostate-specific antigen cut point of 0.4 ng/mL or more.

"A prostate-specific antigen cut point of 0.4 ng/mL or greater reflects the threshold at which a prostate-specific antigen increase becomes durable and shows the strongest correlation with subsequent systemic progression," the authors write.

Abstract
Full Text
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Total Diabetes at 14 Percent in U.S. Adults for 2013-2016

Total Diabetes at 14 Percent in U.S. Adults ...

Prevalence of diagnosed and undiagnosed diabetes 9.7 and 4.3 percent; prevalence increased with age

Novel Immunotherapy May Up Survival in Melanoma Brain Mets

Novel Immunotherapy May Up Survival in Melanoma Brain ...

Findings in patients receiving checkpoint blockade immunotherapy for melanoma brain metastases

Positive Link Between Air Pollution, Diagnosis of Dementia

Positive Link Between Air Pollution, Diagnosis of Dementia

In multipollutant models, only nitrogen dioxide, PM2.5 remained significant

is free, fast, and customized just for you!




Already a member?

Sign In Now »